| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a28a5d5fc3dce057160b54bb3ee0a6fc |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-575
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16171
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6031
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-70 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-167
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-145 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-62
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K19-00 |
| filingDate |
2019-11-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_954cb010abef831077392b9b8843fef6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_373eb557f59e3416e10d9445c9398cf6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f8f11cb22cce094ad24dbee4c7a89395 |
| publicationDate |
2020-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2020039347-A |
| titleOfInvention |
Vaccines based on novel multivalent nanoparticles |
| abstract |
A vaccine based on nanoparticles that elicits an immune response against a wide range of infectious agents, such as influenza viruses. Kind Code: A1 A nanoparticle comprising at least four self-aggregating fusion proteins, each fusion protein being connected to an immunogenic portion of a protein from an infectious pathogen, a self-aggregating monomeric subunit protein. Wherein the immunogenic portion in each type of self-aggregating fusion protein differs from the immunogenic portion in the other type of self-aggregating fusion protein by at least one amino acid residue. All immunogenic moieties in the nanoparticles are derived from corresponding proteins from infectious pathogens of the same taxonomic family, and the nanoparticles have on their surface at least the four self- Nanoparticles that exhibit an immunogenic portion of the aggregating fusion protein. [Selection diagram] None |
| priorityDate |
2014-12-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |